

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](https://www.gov.uk/mhra)

## **Decision Cover Letter**

### **Decision of the licensing authority to:**

grant a product specific waiver

MHRA-100577-PIP01-22

### **Scope of the Application**

#### **Active Substance(s)**

ziltivekimab

#### **Condition(s)**

Treatment of heart failure

#### **Pharmaceutical Form(s)**

All pharmaceutical forms

#### **Route(s) of Administration**

ALL ROUTES OF ADMINISTRATION

#### **Name / Corporate name of the PIP applicant**

Novo Nordisk Ltd

#### **Basis for the Decision**

Pursuant to the Human Medicines Regulations 2012, Novo Nordisk Ltd submitted to the licensing authority on 10/10/2022 13:36 BST an application for a Waiver

The procedure started on 20/02/2023 18:20 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to grant a product specific waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](http://gov.uk/mhra)

## Final Decision Letter

MHRA-100577-PIP01-22

Of 28/02/2023 19:20 GMT

On the adopted decision for ziltivekimab (MHRA-100577-PIP01-22) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Granting a waiver in all age groups for the listed condition

This decision applies to a Waiver for ziltivekimab, All pharmaceutical forms , ALL ROUTES OF ADMINISTRATION .

This decision is addressed to Novo Nordisk Ltd, CMR, 3 City Place, Beehive Ring Road, Gatwick, UNITED KINGDOM, RH6 0PA

## ANNEX I

### 1. Waiver

#### 1.1 Condition:

Treatment of heart failure. The waiver applies / applied to: Paediatric Subset(s): All subsets of the paediatric population from birth to less than 18 years of age. Pharmaceutical form(s): All pharmaceutical forms Route(s) of administration: ALL ROUTES OF ADMINISTRATION Reason for granting waiver: on the grounds that the specific medicinal product is likely to be ineffective.

### 2. Paediatric Investigation Plan:

#### 2.1 Condition(s):

Not Applicable

#### 2.2 Indication(s) targeted by the PIP:

Not Applicable

**2.3 Subset(s) of the paediatric population concerned by the paediatric development:**

Not Applicable

**2.4 Pharmaceutical Form(s):**

Not Applicable

**2.5 Studies:**

<b>Study Type</b>	<b>Number of Studies</b>	<b>Study Description</b>
<b>Quality Measures</b>		
<b>Non-Clinical Studies</b>		
<b>Clinical Studies</b>		
<b>Extrapolation, Modeling &amp; Simulation Studies</b>		
<b>Other Studies</b>		
<b>Other Measures</b>		

**3. Follow-up, completion and deferral of a PIP:**

<b>Concerns on potential long term safety and efficacy issues in relation to paediatric use:</b>	
<b>Date of completion of the paediatric investigation plan:</b>	
<b>Deferral of one or more studies contained in the paediatric investigation plan:</b>	